back to US directory
us clinical guidance

Herpes zoster recognition and early treatment

US diagnosis, timely antiviral treatment, ophthalmic and disseminated-disease escalation, transmission precautions and prevention follow-up.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with suspected localized herpes zoster. Immunocompromised patients, disseminated disease, ocular or neurologic complications, pregnancy exposure and neonatal risk need specialized pathways. Vaccination is addressed only as follow-up prevention because the canonical adult-vaccination page provides the full ACIP schedule.
sources for this section:CDC shingles 2024

The Bottom Line

  • Recognize a painful, pruritic or dysesthetic unilateral vesicular eruption in a dermatomal pattern, while remembering that young and immunocompromised patients may present atypically or without classic vesicles.
  • Diagnose typical zoster clinically and use lesion polymerase-chain-reaction testing when confirmation is important or morphology is atypical; blood serology is not the preferred confirmation of a current lesion.
  • Start appropriate antiviral treatment early because benefit is greatest within 72 hours of symptom onset; consider later treatment when new lesions, high-risk anatomy or complications remain active.
  • Use acyclovir, valacyclovir or famciclovir according to current product labeling, renal function, interactions, age and immune status, alongside individualized acute-pain treatment.
sources for this section:CDC shingles 2024

Practical clinical workflow

1
Record rash onset, pain, prodrome, distribution, eye or ear symptoms, vaccination, immune suppression, pregnancy contacts and exposure to people without varicella immunity; examine the entire skin surface.
2
Identify the dermatome and whether lesions cross multiple nonadjacent areas, inspect the eye and cranial nerves when facial disease is possible, and obtain PCR from a fresh lesion when indicated.
3
Prescribe prompt antiviral and pain management, adjust for kidney function, cover active lesions, reinforce hand hygiene and explain when lesions cease to pose the same transmission risk.
4
Review healing, neuropathic pain and functional impact; address recombinant zoster vaccination under current ACIP recommendations after the acute episode rather than assuming infection provides durable protection.
sources for this section:CDC shingles 2024

Safety boundaries and escalation

  • Forehead, eyelid, nasal-tip, red-eye, photophobia, vision change or ocular pain requires urgent ophthalmic assessment because corneal involvement can threaten vision.
  • Ear vesicles, facial weakness, severe headache, meningism, encephalopathy, motor deficit, urinary retention or disseminated lesions requires urgent neurologic, ENT or hospital evaluation.
  • Use airborne and contact precautions for disseminated disease in healthcare and apply current infection-control guidance for localized lesions in immunocompromised patients; ordinary outpatient advice is insufficient.
  • Avoid giving live varicella-containing vaccine to a susceptible high-risk contact without checking current ACIP contraindications and exposure guidance; prevention decisions are not the same as treatment.
sources for this section:CDC shingles 2024

Localization

CDC clinical guidance and ACIP prevention policy govern US care; Shingrix eligibility, insurance coverage and pharmacy administration vary. State and facility infection-control rules may add requirements for exposed healthcare personnel or congregate settings.
sources for this section:CDC shingles 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionClinical Overview of Shingles (Herpes Zoster)updated 2024-06-27 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.